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Abstract
Burkholderia pseudomallei is the etiological agent of melioidosis, a disease endemic in parts of Southeast Asia and Northern
Australia. Currently there is no licensed vaccine against infection with this biological threat agent. In this study, we
employed an immunoproteomic approach and identified bacterial Elongation factor-Tu (EF-Tu) as a potential vaccine
antigen. EF-Tu is membrane-associated, secreted in outer membrane vesicles (OMVs), and immunogenic during
Burkholderia infection in the murine model of melioidosis. Active immunization with EF-Tu induced antigen-specific
antibody and cell-mediated immune responses in mice. Mucosal immunization with EF-Tu also reduced lung bacterial loads
in mice challenged with aerosolized B. thailandensis. Our data support the utility of EF-Tu as a novel vaccine immunogen
against bacterial infection.
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Introduction
The bacterium Burkholderia pseudomallei is a Gram-negative,
facultative intracellular bacillus and the causative agent of
melioidosis, a serious emerging disease responsible for significant
morbidity and mortality in Southeast Asia and Northern Australia
[1]. Natural infection can occur through subcutaneous inocula-
tion, ingestion, or inhalation of the organism. Clinical manifesta-
tions are nonspecific and widely variable, and may include acute
septicemia, pneumonia, and chronic infection [2]. Mortality rates
associated with severe B. pseudomallei infection approach 50% and
can reach 80–95% in patients with septic shock despite antibiotic
treatment [3,4]. This is partially due to the innate antimicrobial
resistance of B. pseudomallei as well as the intracellular niche of the
organism [1,5]. Thus, preventive measures such as active
immunization are needed to reduce the morbidity and mortality
associated with B. pseudomallei infection.
Previous immunization strategies that utilized heat-killed or live-
attenuated B. pseudomallei, lipopolysaccharide (LPS), capsular
polysaccharide (CPS), or protein-based (i.e. Type III secretion
system (TTSS-3) or outer membrane proteins) subunits conferred
variable degrees of protection against systemic challenge but have
proved ineffective or have not been tested against aerosol infection
[6–13]. In addition, vaccine preparations administered parenterally
with aluminum hydroxide adjuvant elicit robust antibody and Type
2 immune responses against B. pseudomallei but are insufficient for
complete protection [14]. Antibody responses alone are often
deficient in providing sterile immunity against intracellular bacterial
pathogens [15]. An ideal vaccine against B. pseudomallei will likely
require the induction of a Type 1 cellular-mediated immune (CMI)
response for complete efficacy as suggested from past immunization
studies [9,16]. Furthermore, the nasal associated lymphoid tissue
(NALT) may represent a primary site of invasion by B. pseudomallei
[17]. Vaccine strategies that target the mucosal surface and induce
Type 1 responses may therefore provide enhanced protection
against aerosol infection with B. pseudomallei.
Use restrictions associated with B. pseudomallei, a biosafety level
t h r e es e l e c ta g e n t ,h a v eh a m p e r e dv a c c i n ed e v e l o p m e n t .W e
therefore employed an immunoproteomic approach to identify a
number of novel immunoreactive proteins in B. thailandensis that have
potential for useas subunit vaccines against inhalational B.pseudomallei
infection. B. thailandensis shares 94% identity with B. pseudomallei at the
aminoacidlevelandhasservedasausefulsurrogateforB.pseudomallei
in multiple studies [18–22]. Here we report a novel role for bacterial
Elongation Factor-Tu (EF-Tu) as a vaccine immunogen and
demonstrate its ability to elicit antibody and CMI responses in
immunized mice. We also test the protective capacity of EF-Tu
immunization in a B. thailandensis aerosol challenge model [20,21].
Materials and Methods
Ethics Statement
All experimental procedures involving animals were approved
(protocol numbers 4042E and 4048D) and performed under strict
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Health Sciences Center and Tulane National Primate Research
Center Institutional Animal Care and Use Committees.
Two-dimensional gel electrophoresis
Two-dimensional (2D)- gel electrophoresis was performed using
100 mgo fB. thailandensis whole cell lysate solubilized in 7 M urea,
2 M thiourea, 4% (w/v) 3-[3-(cholamidopropyl)dimethylammo-
nio]-1-proanesulphonate (CHAPS), 20% glycerol, 30 mM Tris,
pH 8.5. Fifty mg of the crude lysate was used to rehydrate an
18 cm IPG strip, pH 3–10 non-linear (NL) overnight. The
following day, the proteins in the rehydrated strip were subjected
to isoelectric focusing at 50 mA/strip. The strip was then
equilibrated 15 min with 20 mg/ml dithiothreitol (DTT) and
25 mg/ml iodoacetamide before loading onto a 12.5% SDS-
polyacrylamide gel (Invitrogen). The gel was run for 30 min at
5 Watts/gel and then for 5 hr at 18 Watts/gel. Western blot was
performed as described below with a few modifications: the
membrane was blocked with 5% skim milk in TBS containing
0.05% Tween 20 (TBST); a 1:200 dilution of polyclonal serum
from New Zealand White rabbits that were immunized subcuta-
neously with irradiated B. mallei ATCC 23344 (kindly provided by
Dr. David DeShazer, USAMRIID) was used as the primary
antibody; and a 1:2000 dilution of a goat anti-rabbit HRP-
conjugated antibody (BD Pharmingen, San Diego, CA) was used
as the secondary.
Matrix assisted laser desorption ionization time of flight
(MALDI-TOF) mass spectrometry
MALDI-TOF analysis was performed on a 4700 Proteomics
Analyzer MALDI-TOF-TOF (Applied Biosystems, Foster City,
CA). An averaged simple mass spectrum and tandem mass spectra
from the five most abundant peptides (excluding trypsin autolysis)
of each sample were acquired and manually inspected in Data
Explorer. Global Proteome Server (Applied Biosystems) was
utilized to search the bacteria of Uniprot protein database. One
missed cleavage per peptide was allowed, and the fragment ion
mass tolerance window was set to 100 ppm. A protein hit with a
total score of 75 or higher, with at least one peptide over 20, was
considered a likely match. Protein similarities were obtained using
Basic Local Alignment Search Tools (BLAST) (http://www.ncbi.
nlm.nih.gov/BLAST) and the NCBI non-redundant database.
Cloning, expression, and purification of EF-Tu
Based on the published genome sequence of B. pseudomallei strain
K96243, the complete open reading frame (ORF) of EF-Tu was
PCR amplified from B. pseudomallei strain 286 genomic DNA (BEI
Resources, Manassas, VA) using the forward primer 59-
GCATGCGCCAAGGAAAAGTTTGAGCGGACC-39 and the
reverse primer 59- AAGCTTTTACTCGATGATCTTGGC-
GACGACG -39 which produces SphI and HindIII (underlined)
sites at the 59- and 39- ends of the EF-Tu ORF respectively. The
fragment was ligated into the multi-cloning site of the protein
expression vector pQE30 (Qiagen, Valencia, CA) containing an
N-terminal 6X-histidine tag, and transformed into E.coli strain
DH-5a for automated sequencing using the pQE forward and
reverse sequencing primers (Qiagen). The cloned EF-Tu from
strain 286 shares 100% amino acid sequence identity with EF-Tu
from B. pseudomallei strain K96243 (Uniprot/Swiss prot #Q63PZ6)
and B. thailandensis E264 (Uniprot/Swiss prot #Q2SU25) and
79.4% identity with E. coli K12 (Uniprot/Swiss prot #P0CE48).
For over-expression of the EF-Tu protein, the construct was
transformed into E. coli strain M15 (Qiagen) and transformants
were cultured overnight at 37uC in Luria-Bertani (LB) broth
supplemented with ampicillin (100 mg/ml) and kanamycin (50 mg/
ml). A 1:100 dilution was used to inoculate fresh LB broth
supplemented with ampicillin (50 mg/ml) and kanamycin (25 mg/
ml) and allowed to grow to mid-log phase before induction with
1 mM isopropyl-b-D- thiogalactoside (IPTG) for 4 hr. Cells were
harvested by centrifugation and the cell pellet was stored at
280uC overnight. Cells were resuspended in lysis buffer (50 mM
NaH2PO4, 300 mM NaCl, 10 mM imidazole), and sonicated
three times for 30 sec. Supernatant containing recombinant EF-
Tu (rEF-Tu) protein was collected after centrifugation, and simple
batch purification was achieved using Ni-NTA agarose beads
(Qiagen) under native conditions. Agarose beads were washed
three times with buffer containing 20 mM imidazole, five times
with 0.5% amidosulfobetaine-14 (ASB-14) to remove lipopolysac-
charide (LPS), five times with 20 mM Tris-HCl, and eluted with
250 mM imidazole. Eluted protein fractions were concentrated by
centrifugation (Amicon, MW cutoff 10,000 kDa), and imidazole
was removed by buffer exchange with LPS-free water. LPS
contamination was determined to be less than 25 EU/ml using the
limulus amebocyte lysate (LAL) assay (Lonza, Switzerland).
Protein concentration was determined using the Bradford protein
assay (BioRad).
Total membrane protein extraction, SDS-PAGE, and
Western blot
A single colony of either B. thailandensis or E. coli was used to
inoculate LB broth and incubated overnight. Each culture was
freshly diluted 1:100 into LB broth the next morning. The
bacterial cells were grown to log-phase and harvested by
centrifugation (6,0006g, 10 min, 4uC). The bacterial pellet was
resuspended in 1/50
th volume of 4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid (HEPES) buffer (10 mM, pH 7.4). Lyso-
zyme was added at a final concentration of 10 mg/ml and
incubated for 20 min at room temperature. The bacterial
suspension was sonicated five times (50-Watts) for 30 sec each
on ice. Benzonase (Novagen, Gibbstown, NJ) was added at a final
concentration of 1 mg/ml, and the lysate was incubated for 30 min
at room temperature. Intact cellular debris was removed by
centrifugation (12,0006g, 10 min, 4uC). A sample of the
supernatant consisting of the whole cell lysate was stored at
280uC until use. The remaining supernatant was centrifuged
(50,0006g, 60 min, 4uC), and the resulting pellet was resuspended
in 0.5% Sarkosyl (Sigma) and incubated 30 min at room
temperature. The suspension consisting of total membrane
proteins (both inner and outer membrane) was aliquoted and
stored at 280uC until use.
Sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) was performed using a 4–20% polyacrylamide gel
(Bio-Rad). rEF-Tu or proteins from whole cell lysate or total
membrane fractions of either B. thailandensis or E. coli were
separated under reducing conditions, and the proteins were
subsequently transferred to nitrocellulose membranes. The
membranes were blocked with 1.5% BSA in TBST overnight at
4uC and then washed twice with TBST. The membranes were
then incubated overnight at 4uC with pooled sera (1:200 dilution)
from rEF-Tu immunized mice; pooled sera (1:200 dilution)
obtained from mice 2 weeks after intraperitoneal (i.p.) challenge
with 10
7 cfu B. thailandensis strain E264 (American Type Culture
Collection (ATCC), Manassas, VA); pooled (pre-immune) sera
(1:200 dilution) from naı ¨ve mice; or with a monoclonal antibody
(1:1000 dilution) to the b subunit of E. coli RNA polymerase
(Neoclone, Madison, WI). The RNA polymerase antibody did not
recognize B. thailandensis and was therefore used only on E. coli
Burkholderia EF-Tu
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preparations. The membranes were subsequently washed three
times with TBST and incubated with goat anti-mouse HRP-
conjugated secondary antibody (1:1000 dilution) (Thermo Scien-
tific Pierce, Rockford, IL) for 1 hr at room temperature. The
membranes were washed twice with TBST and developed with
Opti-4CN Substrate (BioRad, Hercules, CA).
Outer membrane vesicle (OMV) preparation
OMVs were prepared as previously described [23,24] with
minor modifications. B. pseudomallei strain 1026b (BEI Resources)
was grown in LB broth at 37uC until late log phase (16–18 hr).
The intact bacteria were pelleted by centrifugation at 6,0006g for
10 min at 4uC, and the supernatant was removed and filtered
through a 0.22 mm polyethersulfone (PES) filter (Millipore) in
order to remove any remaining bacteria or large bacterial
fragments. To ensure the supernatant was free of viable bacteria,
1 mL of supernatant was streaked onto PIA agar and incubated
48–72 hrs at 37uC. The remaining filtered supernatant was
incubated at 4uC. OMVs were harvested by slowly adding
1.5 M solid ammonium sulfate (Fisher Scientific) while stirring
gently and incubated overnight at 4uC. The OMVs were
harvested by centrifugation at 11,0006g for 20 min at 4uC. The
resulting pellet, consisting of crude vesicles, was resuspended in
45% OptiPrep (Sigma) in 10 mM HEPES/0.85% NaCl, pH 7.4,
filter sterilized through a 0.22 mm PES filter and layered at the
bottom of a centrifuge tube. An OptiPrep gradient was prepared
by slowly layering 40%, 35%, 30%, 25%, and 20% OptiPrep in
HEPES-NaCl (w/v) over the crude OMV preparation. Membrane
vesicles were collected by ultracentrifugation at 111,0006g for
2h ra t4 uC. Equal fractions were removed sequentially from the
top and stored at 4uC. To determine the purity of the fractions,
250 ml of each was precipitated with 20% (w/v) Tri-chloroacetic
acid (TCA). The resulting pellet was resuspended in 10 ml
phosphate buffered saline (PBS) and 10 ml Laemmli loading buffer
(Bio-Rad), boiled for 10 min and loaded onto an SDS-PAGE
polyacrylamide gel (4–20% Mini Protean, Bio-Rad) run at 200 V.
The working OMV preparation was recovered by pooling the
peak fractions (those containing the least amount of insoluble
fragments and contaminants) in 50 mM HEPES, pH 6.8 followed
by centrifugation at 111,0006g for 2 hr at 4uC. The resulting
pellet containing OMVs was resuspended in LPS-free water
(Lonza) and stored at 220uC. OMVs were quantified with a
Bradford Protein Assay (Bio-Rad). Cryo-Transmission Electron
Microscopy was performed using a JEOL 2010 transmission
electron microscope to visually confirm the presence of OMVs.
Animals
Female BALB/c mice 8- to 10-weeks-old were purchased from
Charles River Laboratories (Wilmington, MA) and maintained 5
per cage in polystyrene microisolator units under pathogen-free
conditions. Animals were fed sterile rodent chow and water ad
libitum and allowed to acclimate 1 week prior to this study. Mice
were euthanized by carbon dioxide overdose.
Bacterial challenges
Intraperitoneal (i.p.). Prior to murine challenge, B.
thailandensis was freshly grown from frozen glycerol stock in LB
broth overnight and freshly diluted 1:100 into LB broth the next
morning. The bacteria were grown to log-phase and harvested by
centrifugation and diluted into 0.9% NaCl to 1610
8 colony
forming units (cfu)/ml. Each mouse (N=6) was administered
100 ml of bacteria (10
7 cfu) via the i.p. route. Mice were monitored
for symptoms of illness twice daily for 14 days and survivors were
euthanized at the end of study. Blood samples were collected via
cardiac puncture following euthanasia. Blood was allowed to clot
for 30 min at room temperature and then centrifuged at 23006g;
serum was collected and stored at 280uC until use.
Aerosol. BALB/c mice were challenged with 5610
5 cfu
(,LD50)o fB. thailandensis using a nose-only inhalation exposure
chamber as previously described [20,21]. Mice were euthanized at
24 hr post-challenge, and lungs were collected for determination
of lung bacterial cfu.
Immunizations
BALB/c mice (N=70) were primed subcutaneously (s.c.) on day
0 with 25 mg of purified rEF-Tu in LPS-free water adsorbed 1:1
with aluminum hydroxide adjuvant (Alhydrogel 2%, Brenntag,
Germany) in a final volume of 100 ml or intranasally (i.n.) with
25 mg rEF-Tu in LPS-free water admixed with 5 mg CpG
oligodeoxynucleotide (ODN) 1826 adjuvant (Coley, Wellesley,
MA) in a final volume of 9 ml/ nostril. Prior to intranasal
immunization, mice were anesthetized via the i.p. route with
0.88 mg/kg ketamine/xylazine in saline in a final volume of
100 ml. Mice were boosted on day 21 with the same formulations
using a homologous (s.c. + s.c. or i.n. + i.n.) or heterologous (s.c. +
i.n.) prime/boost strategy.
Analysis of antibody response
Blood samples from immunized and naive mice were collected
via cardiac puncture following euthanasia for determination of
rEF-Tu specific serum antibody concentration. Blood was allowed
to clot for 30 min at room temperature and then centrifuged at
23006g; serum was collected and stored at 280uC until assayed.
Bronchoalveolar lavage (BAL) fluid was collected for determina-
tion of rEF-Tu specific BAL antibody concentration. BAL fluid
was obtained by exposing the trachea and making a small incision
into which an 18-gauge needle was inserted and secured. The
lungs were repeatedly lavaged by slowly injecting and withdrawing
1 ml of phosphate buffered saline (PBS) supplemented with
Complete protease inhibitor cocktail (Roche Laboratories, Mann-
heim, Germany). BAL fluid was stored at 280uC until assayed.
The concentrations of serum and BAL fluid rEF-Tu-specific total
IgG, IgG1, IgG2a, and IgA were analyzed by enzyme-linked
immunosorbent assay (ELISA). Ninety-six-well microtiter plates
were coated with 0.5 mg per well of purified rEF-Tu in coating
buffer (0.1 M sodium bicarbonate, 0.2 M sodium carbonate) and
incubated overnight at 4uC. The plates were washed three times
with PBS containing 0.05% Tween-20 (PBST). For measurement
of IgA, plates were additionally blocked with 2% BSA for 1 hr
followed by three washes with PBST. All plates were incubated
with two-fold serial dilutions of sera or BAL samples for 2 hr at
room temperature. Plates were washed three times with PBST and
then incubated with either alkaline phosphatase (AP)-conjugated
rat anti-mouse IgG, IgG1, IgG2a (1:300 dilution in PBST) (BD
Pharmingen) or AP-conjugated goat-anti-mouse IgA (1:2000)
(Invitrogen) for 1 hr at room temperature. At the end of the
incubation, the plates were washed three times with PBST and
developed with SIGMAFAST p-Nitrophenyl phosphate tablets
(Sigma, St. Louis, MO) dissolved in diethanolamine buffer (1 mg/
ml). After 15–30 min of incubation, reaction solutions were
stopped with 2 M NaOH and read at 405 nm using a mQuant
microplate reader and analyzed with Gen5 software (BioTek,
Winooski, VT). Antibody concentrations were determined by non-
linear regression from a standard curve of mouse myeloma IgG1,
IgG2a, and IgA (Sigma) serially diluted as a standard on each
ELISA plate [25]. The results obtained are expressed as the mean
concentration 6 standard error of the mean (SEM).
Burkholderia EF-Tu
PLoS ONE | www.plosone.org 3 December 2010 | Volume 5 | Issue 12 | e14361Antigen restimulation assay
Restimulation assays were performed with splenocytes from
immunized and naı ¨ve mice for analysis of T cell responses. Spleens
were removed aseptically and single-cell splenocyte suspensions
from each mouse were obtained by passing the spleens through
sterile 40 mm cell strainers (Fisher Scientific; Pittsburgh, PA). Cells
were washed twice with wash buffer (Advanced RPMI 1640
medium supplemented with 1% fetal bovine serum (FBS) and 1%
antibiotic-antimycotic) (Invitrogen). Cell pellets were resuspended
in wash buffer and layered onto Histopaque-1119 (Sigma) for
splenic mononuclear leukocyte isolation by centrifugation at
3006g for 15 min. Leukocytes were recovered at the interface
and washed twice with wash buffer and resuspended in Advanced
RPMI 1640 medium supplemented with 10% FBS and 1%
antibiotic-antimycotic. Cells were plated in a 96-well microtiter
plate at 4610
5 cells/well. Cell cultures were stimulated with 1 mg
of rEF-Tu, 1 mg concanavalin A (ConA) (Sigma), or left
unstimulated as negative controls. The cultures were incubated
at 37uCi n5 %C O 2, and cell culture supernatants from each
treatment group were collected after 72 hr and stored at 280u
until use.
CFU recovery
Lung tissue homogenates were used to determine bacterial
burden in aerosol-infected mice. Lungs were aseptically removed,
weighed, and individually placed in 1 ml 0.9% NaCl and
homogenized with a Power Gen 125 (Fisher Scientific). Ten-fold
serial dilutions of lung homogenates were plated on LB agar.
Colonies were counted after incubation for 2–3 days at 37uC and
reported as cfu per gram of tissue.
Statistical analyses
All analyses were performed using GraphPad Prism version 5.0
(GraphPad Software, Inc., La Jolla, CA). Statistical analysis of
cytokine production was performed using a two-way ANOVA,
and analyses of antibody concentrations and bacterial burdens
were performed using the Mann-Whitney test. Values of P,0.05
were considered statistically significant.
Results
Identification of EF-Tu as a potential vaccine candidate
for B. pseudomallei
We employed an immunoproteomic approach [26] to identify
novel immunogenic Burkholderia proteins that could be further
screened for their ability to elicit both antibody and CMI
responses. At that time, antisera against B. pseudomallei was not
available to us. Therefore, pooled antisera from B. mallei-
immunized rabbits was used to probe a B. thailandensis whole cell
lysate that was separated by 2D-gel electrophoresis (Figure 1A).
We hypothesized that proteins shared by B. mallei, B. pseudomallei,
and B. thailandensis could be detected by this approach due to the
extensive homology between the three species [19]. The
immunoblot revealed more than 100 immunoreactive proteins of
which we randomly selected 16 spots for identification by MALDI-
TOF mass spectrometry (Figure 1B). None of the selected spots
were detected using antisera from naı ¨ve rabbits (not shown).
Eleven proteins were successfully identified and share 96–100%
amino acid identity among the three Burkholderia species (Table 1).
Three of the proteins, EF-Tu, AhpC, and DnaK, were previously
recognized as potential B. pseudomallei antigens using a similar
approach with human convalescent sera [27]. Surprisingly, one of
the immunogenic proteins identified by both studies was EF-Tu.
EF-Tu is best known for its role in bacterial protein synthesis,
functioning as a GTPase to catalyze the transfer of aminoacyl-
tRNAs to the ribosome [28]. However, compelling evidence
supports additional functions for EF-Tu, including roles as a
bacterial adhesin and invasin for several pathogenic bacteria
[29–32].
Burkholderia EF-Tu is membrane-associated and
recognized during natural infection
Prior work suggests that B. pseudomallei EF-Tu is present on the
bacterial surface and is recognized by convalescent sera from
human melioidosis patients [27]. Thus, we hypothesized that EF-
Tu may represent a novel immunoprotective antigen. To
determine if EF-Tu is recognized during infection in the murine
model of melioidosis, we infected a group of BALB/c mice (N=6)
intraperitoneally (i.p.) with 10
7 cfu of B. thailandensis and harvested
sera from survivors two weeks later. The pooled sera from infected
mice recognized the recombinant, purified preparation of EF-Tu
(rEF-Tu) (Figure 2A and B), while sera from uninfected mice did
not (not shown). This indicates that EF-Tu is expressed during
infection and is recognized by host antibody in the mouse model.
Furthermore, these observations indicate that host antibody
generated to native EF-Tu during bacterial infection cross-reacts
with rEF-Tu. To determine if rEF-Tu could induce antibodies that
recognize native EF-Tu, we immunized a group of BALB/c mice
(N=6) subcutaneously with 25 mg rEF-Tu adsorbed to aluminum
hydroxide adjuvant and boosted with the same formulation on day
21. On day 35, sera were collected, pooled, and affinity purified
for immunoblot of rEF-Tu, as well as whole cell and total
membrane protein fractions of B. thailandensis. Pooled sera from
rEF-Tu-immunized mice recognized the 47 kDa recombinant
form of EF-Tu, as well as native EF-Tu in the whole cell lysate and
total membrane fraction (Fig. 2C). The bands were excised,
digested, and analyzed by MALDI-TOF mass spectrometry to
confirm their identity. None of the EF-Tu proteins were detected
by Western blot using pooled sera from naı ¨ve BALB/c mice (not
shown). To rule out cytoplasmic EF-Tu contamination in the
membrane fraction, a monoclonal antibody against the b subunit
of E. coli RNA polymerase (NeoClone) was used to probe E. coli
cellular fractions prepared in exactly the same manner as B.
thailandensis. A band at 150 kDa corresponding to the b subunit
was observed in the whole cell lysate and was absent in the total
membrane preparation (Fig. 2D), indicating that the membrane
preparation is free of cytoplasmic contamination.
Burkholderia EF-Tu is secreted in outer membrane
vesicles
EF-Tu has been demonstrated on the surface of several
pathogenic bacteria, including B. pseudomallei and closely-related
Pseudomonas aeruginosa [27,29]. However, we were unsuccessful in
our attempts to demonstrate EF-Tu on the surface of Burkholderia
thailandensis using both immunogold labeling and immunofluor-
esecnt microscopy. EF-Tu lacks a recognizable signal sequence
and the mechanism by which EF-Tu is transported to the bacterial
surface has remained an enigma. Recent work with bacterial
OMVs has demonstrated that OMVs contain numerous virulence
factors, including cytoplasmic, periplasmic, and outer membrane
constituents [33]. We therefore considered the possibility that EF-
Tu, an abundant bacterial protein, might be shed in OMVs.
OMVs were prepared from a late logarithmic culture of B.
pseudomallei strain 1026b (Figure 3A and 3B) and probed with
affinity-purified antibody to EF-Tu. We detected the presence of
EF-Tu in B. pseudomallei OMVs (Figure 3C), which may partially
account for the export of EF-Tu from the bacterial cytoplasm.
Burkholderia EF-Tu
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antigen-specific IgG and IgA
The ability of rEF-Tu to generate antigen-specific IgG that
recognizes the native form of EF-Tu indicates its potential use as a
vaccine immunogen. We therefore designed a mucosal and
parenteral immunization strategy to measure and compare the
antibody and CMI responses elicited by rEF-Tu immunization.
Groups of BALB/c mice (n=12) were primed either subcutane-
ously (s.c.) with 25 mg rEF-Tu adsorbed to aluminum hydroxide or
intranasally (i.n.) with 25 mg rEF-Tu and 5 mg CpG ODN 1826.
CpG ODN is a well-characterized TLR9 ligand that can be
administered parenterally or mucosally to drive type 1 immune
responses [34,35] and can increase vaccine efficacy against B.
pseudomallei [6,36,37]. Adjuvant-only (n=5) and naı ¨ve mice
(n=12) were included as controls. Mice were boosted on day 21
with the same formulations using homologous (s.c. + s.c.; i.n. + i.n.)
and heterologous (s.c. + i.n.) prime-boost strategies. Sera and BAL
fluid from half (n=6) of the animals in the immunized and naı ¨ve
groups were harvested on day 35 and assayed for reactivity with
rEF-Tu by ELISA.
Antigen-specific serum IgG and IgA concentrations were
significantly higher in all immunized groups compared to naı ¨ve
mouse sera (Fig. 4A and 4B; P,0.001). The s.c. + s.c. mice
produced the highest concentrations of EF-Tu-specific serum IgG,
while the i.n. + i.n. mice produced the lowest concentrations
among the immunized groups. In contrast, induction of EF-Tu-
specific serum IgA was only observed in the i.n. + i.n. mice
(Fig. 4B). Antigen-specific IgG and IgA in the BAL was
significantly higher in all immunized groups compared to BAL
from naı ¨ve mice (P,0.001). The s.c. + s.c. group produced the
greatest concentrations of EF-Tu-specific BAL IgG (Fig. 4C). EF-
Tu-specific IgA was more than 100-fold higher in the BAL than in
Figure 1. B. thailandensis whole cell lysate separated by two-dimensional gel electrophoresis. (A) SYPRO-ruby stained gel (B) Western blot
performed using rabbit anti-B. mallei polyclonal sera (1:200 dilution), followed by HRP-conjugated goat anti-rabbit IgG (1:2000) and detected with
Opti-4CN substrate (BioRad).
doi:10.1371/journal.pone.0014361.g001
Burkholderia EF-Tu
PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e14361the serum of immunized animals regardless of the route of
immunization. The median concentration of EF-Tu-specific BAL
IgA was highest in the s.c. + i.n. group, although it was not
statistically different from the other immunized groups (Fig. 4D).
We also assayed IgG1 and IgG2a in the serum and BAL to test
for any differences in the type 1 and type 2 immune responses
elicited in each group. Mice immunized s.c. + s.c. demonstrated
IgG1:IgG2a ratios of 5.6 and 140 in the sera and BAL,
respectively (Table 2). The predominance of IgG1 is more
characteristic of a type 2 immune response [38]. Mice immunized
s.c. + i.n. and i.n. + i.n. displayed serum IgG1:IgG2a ratios of 1.5
and 0.004, respectively, and demonstrated a shift from IgG1 to
IgG2a in the BAL as well (Table 2). These results indicate the
generation of a stronger type 1 immune response in the mucosally
immunized groups versus those immunized parenterally.
Th1 and Th2 cytokine responses in EF-Tu restimulated
splenoctyes
A Th1-driven CMI response, in concert with the production of
specific antibodies, is likely essential for vaccine efficacy against B.
pseudomallei [9,16]. To assess antigen-specific T cell responses in
rEF-Tu immunized mice, spleens were harvested on day 35 (2
weeks post-immunization) and restimulated in vitro with rEF-Tu.
Cell culture supernatants were assayed on day three for IFN-c and
IL-5 production as an indication of Th1 and Th2 responses,
respectively. Mice that were immunized s.c + s.c. produced
significantly higher levels of IL-5 compared to naı ¨ve animals
(Fig. 5A; P,0.05) upon restimulation with rEF-Tu. In contrast,
mice that received one dose of rEF-Tu s.c. and both mouse groups
boosted mucosally (s.c. + i.n. and i.n. + i.n.) produced similar levels
of IL-5 compared to naı ¨ve mice (Fig. 5A). Both groups that were
boosted mucosally (s.c. + i.n. and i.n. + i.n.) produced higher levels
of IFN-c than mice that were immunized parenterally (s.c. only
and s.c. + s.c.) and naı ¨ve mice (Fig. 5B), although this increase was
not statistically significant.
Mucosal immunization with EF-Tu reduces bacterial
burden in the lung
We challenged EF-Tu-immunized mice with B. thailandensis as a
preliminary measure of protective capacity in an in vivo test system.
B. thailandensis is not considered a human pathogen, however it is
lethal in inbred mouse strains (BALB/c and C57Bl/6) at aerosol
challenge doses of 1610
5 cfu or higher [20,21]. We therefore
challenged mice (N=5–6) in immunized, adjuvant-only, and naı ¨ve
groups with 5610
5 cfu (,LD50)o fB. thailandensis by aerosol on
day 35. All mice were sacrificed 24 hr later to assess lung bacterial
burdens since there is a direct correlation between lung bacterial
burden and disease progression in this acute pneumonia model
[20,21]. Mice that were primed s.c. and boosted either s.c. or i.n.
(s.c. + s.c., s.c. + i.n.) had similar numbers of bacteria in the lungs
compared to control mice (Fig. 6). Significantly lower bacterial
burdens in lung tissues were observed in the i.n. + i.n. mice when
compared to the adjuvant only (CpG) and naı ¨ve groups (P,0.05;
Fig. 6).
Discussion
There is currently no effective vaccine against B. pseudomallei,
and traditional vaccine attempts have been largely ineffective at
preventing the inhalational form of disease in animal models [14].
Therefore, alternative vaccination strategies that incorporate
recent advances in adjuvant biology and mucosal immunology
deserve investigation. Our approach employed immunoproteo-
mics to identify proteins that could be utilized as subunit vaccine
antigens and delivered mucosally. Of the 11 proteins that we
Table 1. Immunoreactive B. thailandensis proteins identified by MALDI-TOF mass spectrometry.
Sample
Number Protein
Accession
Number Function
Theoretical
MW (kDa)
Theoretical
pI
% identity to B.
pseudomallei K96243
% identity to B.
mallei ATCC 23344
1 DnaK 83721009 heat shock protein 69.70 4.96 98% 98%
2 HtpG 83720569 heat shock protein 70.97 5.17 99% 99%
3 30S ribosomal protein 83719745 translation 62.26 5.08 100% 100%
4 3-oxoadipate CoA-
succinyl transferase
83721125 metabolism 33.16 9.06 98% 98%
5 AhpC 83721537 peroxidase 23.81 5.61 98% 98%
6 *
7 *
8 hypothetical protein
BTH_110718
83717445 11.87 5.64 not present not present
9 OmpW 83719376 outer membrane
protein
22.71 8.6 96% 96%
10 cpn10 83719093 heat shock protein 10.48 5.33 99% 99%
11 CmaB 83717262 translation 35.36 5.44 97% not present
12 ribosomal protein L7 83719193 translation 12.52 4.9 97% 98%
13 *
14 *
15 *
16 EF-Tu 83721154 translation 42.86 5.36 100% 100%
Putative function and % identity to B. pseudomallei K96243 and B. mallei ATCC 23344 at the amino acid level are shown. Proteins in bold were also identified by Harding
et al. [27] using a similar approach. * unidentified by mass spectrometry. ‘‘Not present’’ indicates that no known ortholog is annotated in the NCBI genomic database.
doi:10.1371/journal.pone.0014361.t001
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recognized by Harding et al. [27] using a similar approach with
convalescent sera from melioidosis patients. The co-recognition of
these particular B. pseudomallei antigens by two independent
laboratories reinforces their potential value as vaccine immuno-
gens. We therefore selected one of the three, EF-Tu, as our first
test antigen since both AhpC and DnaK have received
considerable attention elsewhere for related bio-threat agents
[39–42].
Its traditional cytoplasmic role in protein synthesis would render
EF-Tu an unlikely candidate for a protective subunit vaccine.
However, EF-Tu is one of the most abundant and conserved
bacterial proteins (100% amino acid identity among B. thailanden-
sis, B. mallei, and five different strains of B. pseudomallei – Table 1
and Files S1 and S2) and is a major component of the bacterial
membrane cytoskeleton [43,44]. EF-Tu comprises as much as 5–
10% of the cytoplasmic protein in all bacteria investigated, and it
may be functionally analogous to actin as it can polymerize into
Figure 2. Immunogenicity of EF-Tu during infection and immunization. (A) Coomassie stained gel of rEF-Tu affinity purified under native
conditions by Ni-NTA agarose batch purification. MW=BenchMark Pre-stained molecular weight ladder; Whole-cell lysate (WCL)=5 mg; Flow-through
(FT)=5 mg; Washes 1, 3, and 5 with 20 mM imidazole (W1, W2, W3); Elutions 1 and 2 with 250 mM imidazole (E1, E2)=5 mg. (B) Western blot of 10 mg
rEF-Tu probed with pooled sera from BALB/c mice infected i.p. with 10
7 cfu of B. thailandensis (1u Ab, 1:200; 2u Ab 1:1000). MW=BenchMark Pre-
stained molecular weight ladder. (C) Western blot of 0.5 mg rEF-Tu, 15 mg B. thailandensis whole cell lysate (WCL) and 15 mg B. thailandensis total
membrane protein (TMP) fractions probed with pooled antisera from rEF-Tu-immunized mice (1u Ab, 1:200; 2u Ab, 1:1000). MW=SeeBlue Plus2
molecular weight ladder. (D) Western blot of 0.5 mg rEF-Tu, 15 mg E. coli WCL and 15 mg E. coli TMP fractions probed with monoclonal antibody to E.
coli b subunit of RNA Polymerase (1u Ab, 1:1000; 2u Ab, 1:1000). MW=SeeBlue Plus2 molecular weight ladder.
doi:10.1371/journal.pone.0014361.g002
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demonstrates that EF-Tu may play a previously under-appreciated
roleas a bacterial virulencefactor.For example,surface-translocated
EF-Tu mediates binding to fibronectin and other host proteins for
Mycoplasma pneumoniae and Pseudomonas aeruginosa, and EF-Tu can
facilitate invasion of host cells by Francisella tularensis via interaction
with nucleolin [29,30,32]. Furthermore, immunoproteomic-based
approaches for antigen discovery against other intracellular bacterial
pathogens have identified EF-Tu as an immunodominant protein
[46,47]. Taken together, these studies lend support to our
observations of immunogenic EF-Tu in the membrane of B.
thailandensis and that reported elsewhere for B. pseudomallei [27].
Although we were unable to demonstrate EF-Tu on the surface of B.
thailandensis, we did observe EF-Tu in the OMVs shed from B.
pseudomallei during in vitro growth. This may partially account for the
generation of host antibody against EF-Tu since OMVs have been
observed to activate B cells [33]. In this study, active immunization
of mice with EF-Tu generated high concentrations of antigen-
specific IgG that recognized both the recombinant and native forms
of EF-Tu. As far as we know, this work is the first application and
evaluation of EF-Tu as a vaccine immunogen for a bacterial
pathogen.Like the bacterial antigens, flagellinand LPS (both highly-
evaluated as vaccine constituents), EF-Tu is abundantly present and
highly immunogenic during B. pseudomallei infection in humans [27]
and animal models of melioidosis and thus deserves investigation.
Furthermore, bacterial EF-Tu and human EF2 share only 17%
identity at the amino acid level and are not functionally
interchangeable (File S1) [44]. We also observed no cross-reactivity
of EF-Tu-specific antibody with mammalian tissue by Western blot
(File S3). Thus, the potential for bacterial EF-Tu to induce
autoimmune disease in vaccinated individuals appears negligible.
Our heterologous and homologous prime/boost immunization
studies compared the traditional parenteral route of immunization
with aluminum hydroxide as the adjuvant to an intranasal
formulation of rEF-Tu admixed with CpG ODN, an adjuvant
capable of polarizing the immune response to Th1 and enhancing
mucosal IgA, systemic antibody, and T cell immunity [34,35]. It
has been proposed that B. pseudomallei may utilize the NALT as a
portal of entry in murine melioidosis [17]. Therefore, the i.n. route
of immunization may better prevent mucosal infections through
the priming and activation of local antimicrobial immunity. To
test this hypothesis, we challenged both parenterally and mucosally
immunized mice with 5610
5 cfu of B. thailandensis using a nose-
only inhalation exposure chamber. We and others have previously
demonstrated that aerosol infection of BALB/c mice with B.
thailandensis is an excellent surrogate model for the acute
pneumonic form of disease caused by B. pseudomallei and is capable
of reproducing the major lung pathology of murine melioidosis
[20,21]. Furthermore, there is a direct correlation between lung
bacterial burden and disease progression in the murine model
[20,21]. The reduced bacterial numbers observed only in the lungs
of mice that were immunized mucosally with EF-Tu/CpG
suggests that EF-Tu immunization may influence protection and
that the route of immunization may be critical. Moreover, the
early reduction in bacterial burden in the i.n. + i.n. group cannot
exclusively be attributed to the immunoprotective capacity of CpG
[48] because mice immunized i.n. with CpG ODN 1826 alone
had similar, if not slightly higher, numbers of bacteria compared to
naı ¨ve mice that were challenged (Fig. 6).
Past vaccine attempts against B. pseudomallei failed to confer
complete protection despite the induction of a robust antibody
response; however, humoral immunity will likely be an essential
component of any vaccine against this organism [16]. Previous
work demonstrated a 0% survival rate in mice immunized with B.
pseudomallei-pulsed dendritic cells though the immunization
generated a substantial cell-mediated immune response [16].
Figure 3. EF-Tu is present in B. pseudomallei outer membrane vesicles. (A) Cryo-transmission electron micrograph of purified OMVs prepared
from a late logarithmic culture of B. pseuodomallei strain 1026b. Bar indicates 100 nm. (B) Coomassie-stained gel of OMV preparation (5 mg);
MW=SeeBlue plus2 molecular weight ladder. (C) Western blot of OMV preparation using affinity purifed EF-Tu antibody (1:1000).
doi:10.1371/journal.pone.0014361.g003
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heat-killed bacteria and correlated with the production of high B.
pseudomallei-specific antibody titers [16]. Immunization with EF-Tu
yielded high concentrations of antigen-specific IgG in the sera and
BAL by both the parenteral and mucosal immunization regimens.
However, EF-Tu-specific IgG levels did not correlate with the
observed differences in lung bacterial burdens in immunized mice
in our study. In addition to IgG, secretory IgA may play a role in
protection against inhalational pathogens as previously demon-
strated for Bordetella pertussis [49]. Undetectable to very low levels of
EF-Tu-specific IgA were observed in the sera of immunized mice
regardless of the route of immunization. In contrast, EF-Tu-
specific IgA was significantly elevated in the BAL of immunized
mice compared to naı ¨ve mice, but there was no statistical
difference among any of the immunized groups. Therefore, IgA
concentrations also may not account for the differences observed
in lung bacterial burdens at the time point examined.
Although antibodies contribute to protection against B.
pseudomallei [16] a robust CMI response is likely required for
ultimate clearance of internalized bacteria [16,50]. Antigen-
specific T cells, particularly CD4
+ T cells, are important sources
of IFN-c and are essential for host resistance to acute and chronic
infection with B. pseudomallei [50]. EF-Tu was recently shown to
Figure 4. rEF-Tu-specific IgG and IgA concentrations in sera and BAL of immunized mice. Serum IgG (A) and IgA (B) and BAL IgG (C) and
IgA (D) were measured by ELISA. SC=subcutaneous immunization with 25 mg rEF-Tu adsorbed 1:1 with aluminum hydroxide adjuvant. IN=intranasal
immunization with 25 mg rEF-Tu admixed with 5 mg CpG adjuvant. Horizontal line represents the median value for each group (N=6). Median values
are provided in parentheses for IN + IN and naı ¨ve groups in panels A and C. (*P,0.05, **P,0.01, ***P,0.001 using the Mann-Whitney test).
doi:10.1371/journal.pone.0014361.g004
Table 2. Serum and BAL EF-Tu specific IgG1 and IgG2a
concentrations (mg/ml) and ratios.
Serum BAL
Group IgG1 IgG2a ratio IgG1 IgG2a ratio
SC 124.5 13.7 9.1 0.47 0.22 22
SC+SC 333.7 59.6 5.6 3.7 0.02 140
SC+IN 93.0 63.2 1.5 1.5 0.04 31
IN+IN 0.28 63.3 0.004 0.07 0.009 8.4
IgG1 and IgG2a were measured by ELISA using sera and BAL from immunized
mice (N=6). IgG1:IgG2a ratios .1 indicate a type 2 humoral immune response,
while ratios ,1 indicate a type 1 cellular immune response.
doi:10.1371/journal.pone.0014361.t002
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+ T cells in cattle immunized with outer
membrane protein preparations of the rickettsial pathogen,
Anaplasma marginale [51]. Our work corroborates their findings as
we demonstrated both Th1 (IFN-c) and Th2 (IL-5) cytokine
production in EF-Tu-restimulated splenocytes that reflected both
the adjuvant used and the route of immunization. In other words,
the parenteral immunization strategy that incorporated aluminum
hydroxide as adjuvant promoted Th2 responses to rEF-Tu, while
the mucosal administration of rEF-Tu with CpG polarized the
immune response towards Th1. This is also supported by the
IgG1:IgG2a ratios in the sera and BAL that demonstrated a Th1
polarization in mucosally immunized mice (Table 2). These results
are not entirely unexpected, and it is plausible that the antigen-
specific Th1 response elicited by mucosal immunization with rEF-
Tu/CpG is responsible for the reduced bacterial burden observed
early in the lungs of the i.n. + i.n. group. Considering the
predominance of EF-Tu in the bacterial cell, further analysis of
EF-Tu-specific CD4
+ T memory cells is clearly warranted.
The lack of adequate treatment and prevention against melioidosis
necessitates the development of a vaccine against B. pseudomallei [14].
Inhalation of B. pseudomallei is a natural route of infection, and it
represents the primary route of exposure in a deliberate biological
Figure 5. Th1 and Th2 cytokine responses to rEF-Tu in restimulated splenocytes from immunized mice. Splenocytes from individual
mice in each treatment group (N=6) were restimulated in triplicate with rEF-Tu (1 mg) or ConA (1 mg) or left unstimulated, and cell culture
supernatants were assayed in duplicate on day 3 for IL-5 (A) and IFN-c (B) cytokine production using a multiplex assay. Error bars represent the
standard error of the mean (SEM) for each group (*P,0.05 using a two-way ANOVA).
doi:10.1371/journal.pone.0014361.g005
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this route of infection. We identified EF-Tu, a protein best recognized
for its role in bacterial protein synthesis, as a subunit vaccine candidate
against pathogenic Burkholderia. Our data indicate that recombinant
EF-Tu is immunogenic, inducing antigen-specific antibody and CMI
responses. To our knowledge, this is the first in vivo demonstration of
the utility of bacterial EF-Tu as a vaccine immunogen. Mucosal
immunization with EF-Tu/CpG reduced lung bacterial loads in mice
challenged with a lethal dose of B. thailandensis by aerosol. Further
immunization and challenge studies with virulent B. pseudomallei will
examine the protective efficacy of EF-Tu and represent the next steps
in evaluation of EF-Tu as a viable vaccine candidate.
Supporting Information
File S1 Elongation factor Tu amino acid alignment and percent
identity for Burkholderia thailandensis, B. pseudomallei, B. mallei,
E. coli, and Homo sapiens.
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File S2 Elongation factor Tu amino acid alignment and percent
identity among five sequenced isolates of B. pseudomallei.
Found at: doi:10.1371/journal.pone.0014361.s002 (0.03 MB
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File S3 Antibody against bacterial EF-Tu does not react with
mammalian tissue. (A) Coomassie stained gel of mouse lung (Lu),
liver (Lv), and spleen (S) homogenates. MW=SeeBlue plus2
molecular weight ladder. (B) Western blot of mouse tissues using
1:100 dilution of affinity purified EF-Tu IgG.
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